From: Association of CYP1B1 L432V polymorphism with urinary cancer susceptibility: a meta-analysis
First author, year | Country | Ethnicity | Source of control | Cases/controls | MAF of controls | Powera | Source of DNA | Genotyping methods |
---|---|---|---|---|---|---|---|---|
Prostate cancer | ||||||||
Holt, 2013 | USA | Caucasian | PB | 1256/1235 | 0.41 | 1 | blood | SNPlex |
Catsburg C, 2012 | USA | Caucasian | PB | 1433/760 | 0.47 | 1 | blood | Taqman |
Beuten J, 2008 | USA | Caucasian | PB | 649/738 | 0.39 | 1 | blood | Taqman |
Berndt, 2007 | USA | Mixed | PB | 486/611 | 0.47 | 1 | blood | TaqMan |
Cussenot O, 2007 | France | Caucasian | HB | 1053/837 | 0.39 | 1 | blood | TaqMan |
Sobti RC, 2006 | India | Asian | PB | 100/100 | 0.18 | 0.415 | blood | PCR–RFLP |
Cicek MS, 2005 | USA | Mixed | HB | 439/479 | 0.47 | 1 | blood | PCR–RFLP |
Fukatsu, 2004 | Japan | Asian | HB | 136/255 | 0.29 | 0.947 | blood | PCR–RFLP |
Chang BL, 2003 | USA | Mixed | HB | 310/182 | 0.44 | 0.807 | ND | Sequencing |
Tanaka Y, 2002 | Japan | Asian | PB | 117/200 | 0.18 | 0.857 | ND | AS-PCR |
Bladder cancer | ||||||||
Berber U, 2013 | Turkey | Asian | PB | 114/114 | 0.27 | 0.499 | tissue | AS-PCR |
Salinas-Sánchez AS, 2012 | Spain | Caucasian | HB | 208/208 | 0.39 | 0.875 | blood | Sequencing |
Fontana L, 2009 | France | Caucasian | HB | 51/45 | 0.58 | 0.104 | blood | TaqMan |
Figueroa J, 2008 | Spain | Caucasian | HB | 1084/1012 | 0.42 | 1 | blood/buccal | TaqMan |
Hung RJ, 2004 | Italy | Caucasian | HB | 201/214 | 0.59 | 0.888 | ND | PCR–RFLP |
Renal cancer | ||||||||
Salinas-Sánchez AS, 2012 | Spain | Caucasian | HB | 126/208 | 0.39 | 0.875 | blood | Sequencing |
Sasaki M, 2005 | USA | Asian | HB | 211/200 | 0.18 | 0.857 | tissue | AS-PCR |